Figlin R - Search Results

1

Mentoring junior faculty in geriatric oncology: report from the Cancer and Aging Research Group.

Hurria A, Balducci L, Naeim A, Gross C, Mohile S, Klepin H, Tew W, Downey L, Gajra A, Owusu C, Sanati H, Suh T, Figlin R. Hurria A, et al. Among authors: figlin r. J Clin Oncol. 2008 Jul 1;26(19):3125-7. doi: 10.1200/JCO.2008.16.9771. J Clin Oncol. 2008. PMID: 18591553 Free PMC article. No abstract available.

2

Systemic therapies for metastatic renal cell carcinoma in older adults.

Pal SK, Vanderwalde A, Hurria A, Figlin RA. Pal SK, et al. Drugs Aging. 2011 Aug 1;28(8):635-49. doi: 10.2165/11592880-000000000-00000. Drugs Aging. 2011. PMID: 21812499 Free PMC article. Review.

3

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-Del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Motzer RJ, et al. Among authors: figlin ra. J Clin Oncol. 2023 Apr 10;41(11):1965-1971. doi: 10.1200/JCO.22.02623. J Clin Oncol. 2023. PMID: 37018919

4

Measuring the incremental cost of clinical cancer research.

Goldman DP, Schoenbaum ML, Potosky AL, Weeks JC, Berry SH, Escarce JJ, Weidmer BA, Kilgore ML, Wagle N, Adams JL, Figlin RA, Lewis JH, Cohen J, Kaplan R, McCabe M. Goldman DP, et al. Among authors: figlin ra. J Clin Oncol. 2001 Jan 1;19(1):105-10. doi: 10.1200/JCO.2001.19.1.105. J Clin Oncol. 2001. PMID: 11134202

5

Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma.

Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS. Zisman A, et al. J Clin Oncol. 2002 Dec 1;20(23):4559-66. doi: 10.1200/JCO.2002.05.111. J Clin Oncol. 2002. PMID: 12454113

6

Temsirolimus for advanced renal cell carcinoma.

Figlin RA. Figlin RA. Clin Adv Hematol Oncol. 2007 Nov;5(11):893. Clin Adv Hematol Oncol. 2007. PMID: 18185488 No abstract available.

7

Bevacizumab plus interferon alpha in patients with metastatic renal cell carcinoma.

Twardowski P, Figlin RA. Twardowski P, et al. Nat Clin Pract Oncol. 2008 Aug;5(8):436-7. doi: 10.1038/ncponc1162. Epub 2008 Jun 17. Nat Clin Pract Oncol. 2008. PMID: 18560387 No abstract available.

8

Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.

Figlin RA. Figlin RA. Nat Clin Pract Oncol. 2008 Oct;5(10):601-9. doi: 10.1038/ncponc1173. Epub 2008 Jul 8. Nat Clin Pract Oncol. 2008. PMID: 18607393 Review.

9

Anti-angiogenic therapy in renal cell carcinoma: Alone, in combination, or sequentially.

Figlin RA. Figlin RA. Clin Adv Hematol Oncol. 2009 Oct;7(10):662-5. Clin Adv Hematol Oncol. 2009. PMID: 20040906 No abstract available.

10

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.

Pal SK, Figlin RA. Pal SK, et al. Clin Med Insights Oncol. 2010 Jun 9;4:43-53. doi: 10.4137/cmo.s1590. Clin Med Insights Oncol. 2010. PMID: 20711245 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

397 results

Search Page